Veraxa Biotech AG VRXA 深 滬
等待開盤 11-05 09:30:00 美东时间
0.95
-0.040
-4.04%
華盛通- 最 高1.0175
- 今 開0.9901
- 成交量 10.31万股
- 最 低 0.95
- 昨 收 0.99
- 總市值 1.34亿
- 52周最高 27.36
- 市盈率 靜 3.34
- 換手率 0.07%
- 52周最低 0.95
- 委 比 97.88%
- 總股本 1.41亿
- 歷史最高 27.36
- 量 比 0.50
- 振 幅 6.82%
- 歷史最低 0.95
- 每 手 1
- 風險率 4.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing
Austin, Texas, United States, October 7th, 2026, FinanceWire VERAXA Biotech (NA...
10-08 01:00
VERAXA Biotech names Raju Willener as CFO
VERAXA (VRXA) said on Friday it appointed Raju Willener as CFO, effective immediately, succeeding Carl von Halem, former CFO. Willener brings more than 30 years of international experience across inve...
09-04 19:07
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announc...
08-24 19:10
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures
Austin, Texas, United States, July 28th, 2026, FinanceWire VERAXA Biotech (NASD...
07-29 01:00
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
Austin, Texas, United States, July 27th, 2026, FinanceWire VERAXA Biotech (NASD...
07-28 02:30
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer
Austin, Texas, United States, July 24th, 2026, FinanceWire VERAXA Biotech (NASD...
07-25 01:00
VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA))), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding the underlying biology and proposed non-clinical development pl...
07-20 19:09
VERAXA Biotech appoints interim CFO
VERAXA Biotech (VRXA) appointed Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister Carl von Halem currently serves as CFO of Xlife Sciences and played a key role in VE...
07-11 04:11
VERAXA Biotech Appoints Carl Von Halem As Interim CFO, Succeeding Torsten Bürgermeister
VERAXA Biotech AG (NASDAQ:VRXA, "VERAXA"))), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim Chief Financial Officer. He succeeds Torsten Bürgermeister. The company is currently in the final stages of discussions with a highly qual...
07-11 04:06
